Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 773-780

  Vega, Kenneth J ^a   May, Randal ^a,c   Sureban, Sripathi M ^a,c   Lightfoot, Stan A ^a,c   Qu, Dongfeng ^a   Reed, Alessandra ^a   Weygant, Nathaniel ^a   Ramanujam, Rama ^d   Souza, Rhonda ^f   Madhoun, Mohammad ^a   Whorton, Joshua ^a   Anant, Shrikant ^e   Meltzer, Stephen J ^g   Houchen, Courtney W ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Peggy and Charles Stephenson Oklahoma Cancer Institute   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ADNA Inc   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; Cancer; Doublecortin and CaM kinase like 1; Esophageal adenocarcinoma; Esophagus; Leucine rich repeat containing G protein coupled receptor; Musashi 1; Stem cell marker

Indexed keywords

DOUBLECORTIN AND CAM KINASE LIKE 1 PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL; STROMA CELL; UPREGULATION;

EID: 84858832154     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06928.x     Document Type: Article

References (28)

1. Sharma P, McQuaid K, Dent J etal. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 2005; 97: 142-6.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009; 59: 225-49.
4. Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin. Proc. 2001; 76: 438-46.
5. Rex DK, Cummings OW, Shaw M etal. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670-7.
6. Ronkainen J, Aro P, Storskrubb T etal. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-31.
7. Kubo A, Levin TR, Block G etal. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009; 136: 806-15.
8. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin. Gastroenterol. Hepatol. 2005; 3: 1-10.
9. van Dekken H, Hop WC, Tilanus HW etal. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am. J. Clin. Pathol. 2008; 130: 745-53.
10. Sharma P. Clinical practice. Barrett's esophagus. N. Engl. J. Med. 2009; 361: 2548-56.
11. Mendelson J, Song S, Li Y etal. Dysfunctional transforming growth factor-beta signaling with constitutively active notch signaling in Barrett's esophageal adenocarcinoma. Cancer 2011; 117: 3691-702.
12. Grotenhuis BA, Dinjens WN, Wijnhoven BP etal. Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J. Pathol. 2010; 221: 379-89.
13. Bobryshev YV, Freeman AK, Botelho NK, Tran D, Levert-Mignon AJ, Lord RV. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma. Dis. Esophagus 2010; 23: 580-9.
14. Sureban SM, May R, Ramalingam S etal. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 2009; 137: 649-59.
15. Sureban SM, May R, Lightfoot S etal. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011; 71: 2328-38.
16. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008; 26: 630-7.
17. May R, Sureban SM, Lightfoot SA etal. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 299: G303-10.
18. von Rahden BH, Kircher S, Lazariotou M etal. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? J. Exp. Clin. Cancer Res. 2011; 30: 23-33.
19. Becker L, Huang Q, Mashimo H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis. Esophagus 2010; 23: 168-74.
20. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999; 340: 825-31.
21. Rossi M, Barreca M, de Bortoli N etal. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann. Surg. 2006; 243: 58-63.
22. Barbera M, Fitzgerald RC. Cellular origin of Barrett's metaplasia and oesophageal stem cells. Biochem. Soc. Trans. 2010; 38: 370-3.
23. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 295: G211-18.
24. Hutchinson L, Stenstrom B, Chen D etal. Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts and endothelium can arise from bone marrow derived cells after allogeneic stem cell transplant. Stem Cells Dev. 2010; 20: 11-7.
25. Ell C, May A, Gossner L etal. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 670-7.
26. Pech O, Behrens A, May A etal. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57: 1200-6.
27. Shaheen NJ, Sharma P, Overholt BF etal. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 2009; 360: 2277-88.
28. Cronin J, McAdam E, Danikas A etal. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am. J. Gastroenterol. 2011; 106: 46-56.